Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Impact of Kidney Dysfunction on Overall Survival in Myeloproliferative Neoplasms: A Single-Center Retrospective Study

Eshrak Al-Shaibani, Taylor Young, Eshetu Atenafu, Verna Cheung, Safwan Alsibai, Vikas Gupta, Dawn C. Maze, Marta Beata Davidson, Aniket Banker, Hassan Sibai

Blood (2023) 142 (Supplement 1): 6439.

https://doi.org/10.1182/blood-2023-189318

Published: 2023

Journal Articles

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Josephine Anne Lucero, Aniket Bankar, Marta Beata Davidson, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Dawn C. Maze, Karen Yee, Mark D. Minden, Steven M. Chan, Jonas Mattsson, Rajat Kumar, Vikas Gupta, Jose-Mario Capo-Chichi, Tracy Stockley, Hassan Sibai, Anne Maria Tierens, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2023-190694

Published: 2023

Journal Articles

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Guillaume Richard-Carpentier, Gopila Gupta, Charina Cameron, Severine Cathelin, Aniket Bankar, Marta Beata Davidson, Vikas Gupta, Dawn C. Maze, Mark D. Minden, Tracy Murphy, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Joseph Brandwein, Caroline Jane McNamara, Steven M. Chan

Blood (2023) 142 (Supplement 1): 159.

https://doi.org/10.1182/blood-2023-188341

Published: 2023

Journal Articles

Clinical Outcomes in De Novo Versus Secondary NPM1 -Mutated AML

Elliot C. Smith, Eshetu G. Atenafu, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn Maze

Blood (2022) 140 (Supplement 1): 8952–8953.

https://doi.org/10.1182/blood-2022-166939

Published: 2022

Journal Articles

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Maria Agustina Perusini, Eshetu G. Atenafu, Aniket Bankar, Vikas Gupta, Mark D. Minden, Jad Sibai, Dawn Maze, Marta B. Davidson, Steven M. Chan, Fernando Binder, Guillaume Richard-Carpentier, Salman Alharbi, Claire Andrews, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3176–3177.

https://doi.org/10.1182/blood-2022-170121

Published: 2022

Journal Articles

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Fatima M Khadadah, Claire Andrews, Eshetu G. Atenafu, Andre C. Schuh, Dawn Maze, Karen Yee, Osamah Jamal S. Jarallah, Mark D. Minden, Aaron D. Schimmer, Steven M. Chan, Vikas Gupta, Dennis Dong Hwan Kim, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3169–3171.

https://doi.org/10.1182/blood-2022-169342

Published: 2022

Journal Articles

Which Asparaginase Formulation Retained Higher VTE Incidence Risk in Post Treatment Adult Acute Lymphoblastic Leukemia? a Meta-Analysis

Jack T Seki, Reem Alsibai, Ruiqi Chen, Eshetu G. Atenafu, Hassan Sibai

Blood (2022) 140 (Supplement 1): 8898–8899.

https://doi.org/10.1182/blood-2022-167560

Published: 2022

Journal Articles

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Blood (2022) 140 (Supplement 1): 9122–9124.

https://doi.org/10.1182/blood-2022-171107

Published: 2022

Journal Articles

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Kenny Tang, Dawn Maze, Karen Yee, Hassan Sibai, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Andre C. Schuh, Aniket Bankar, Guillaume Richard-Carpentier, Anne Tierens, Mark D. Minden, Vikas Gupta, Jeffrey H. Lipton, Dennis Kim

Blood (2022) 140 (Supplement 1): 9608–9610.

https://doi.org/10.1182/blood-2022-166416

Published: 2022

Journal Articles

Multiparameter Flow Cytometry-Based Residual Disease Analysis Identifies Intermediate-Risk AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Josephine Anne Lucero, Anne Tierens, Muhned Alhumaid, Jose-Mario Capo-Chichi, Tracy L. Stockley, Vikas Gupta, Steven M. Chan, Andre C. Schuh, Mark D. Minden, Jonas Mattsson, Rajat Kumar, Hassan Sibai, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 11797–11798.

https://doi.org/10.1182/blood-2022-168260

Published: 2022

Journal Articles

Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

James T. England, Eshetu G. Atenafu, James A. Kennedy, Burhan Goraya, Verna Cheung, Taylor Nye, Karine Gauthier, Marta B. Davidson, Aniket Bankar, Hassan Sibai, Dawn Maze, Auro Viswabandya, Vikas Gupta

Blood (2022) 140 (Supplement 1): 9724–9725.

https://doi.org/10.1182/blood-2022-165272

Published: 2022

Journal Articles

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Maria Agustina Perusini, Jad Sibai, Eshetu G. Atenafu, Aniket Bankar, Mark D. Minden, Vikas Gupta, Dawn Maze, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Guillaume Richard-Carpentier, Josephine Anne Lucero, Claire Andrews, Dennis Dong Hwan Kim, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 6039–6041.

https://doi.org/10.1182/blood-2022-169406

Published: 2022

Journal Articles

Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis

Jessie J.F. Medeiros, Andy G.X. Zeng, Michelle Chan-Seng-Yue, Tristan Woo, Jessica L McLeod, Andrea Arruda, Hubert Tsui, Burhan Goraya, Jaime O. Claudio, Jenny M. Ho, James A. Kennedy, Dawn Maze, Hassan Sibai, Mark D. Minden, Jean C.Y. Wang, John E. Dick, Vikas Gupta

Blood (2022) 140 (Supplement 1): 9681–9682.

https://doi.org/10.1182/blood-2022-163722

Published: 2022

Journal Articles

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Josephine Anne Lucero, Brayan Merchán, Osamah Jamal S. Jarallah, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Dawn Maze, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3166–3168.

https://doi.org/10.1182/blood-2022-168488

Published: 2022

Journal Articles

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Salman Alharbi, Maria Agustina Perusini, Sita Bhella, Mark D. Minden, Dawn Maze, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Steven M. Chan, Aniket Bankar, Marta B. Davidson, Guillaume Richard-Carpentier, Jad Sibai, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3187–3188.

https://doi.org/10.1182/blood-2022-168662

Published: 2022

Journal Articles

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Francesco Passamonti, James M. Foran, Anand Tandra, Valerio De Stefano, Maria Laura Fox, Ahmad H. Mattour, Mary Frances McMullin, Andrew Charles Perkins, Gabriela Rodríguez-Macias, Hassan Sibai, Qin Qin, Yan Sun, Jalaja Potluri, Jason Harb, Jonathan How

Blood (2022) 140 (Supplement 1): 583–585.

https://doi.org/10.1182/blood-2022-157949

Published: 2022

Journal Articles

Germline Testing for Patients with Familial MPN: A Single-Center Experience

Safa Ansar, Janet Malcolmson, Kirsten M Farncombe, Karen Yee, Raymond H Kim, Hassan Sibai

Blood (2022) 140 (Supplement 1): 6879–6880.

https://doi.org/10.1182/blood-2022-162430

Published: 2022

Journal Articles

Enasidenib in Combination with Venetoclax in IDH2 -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial

Steven M Chan, Charina Cameron, Severine Cathelin, Vikas Gupta, Dawn Maze, Mark D. Minden, Tracy Murphy, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Caroline J McNamara

Blood (2021) 138 (Supplement 1): 1263.

https://doi.org/10.1182/blood-2021-153660

Published: 2021

Journal Articles

Safety and Efficacy of JAK Inhibitor Therapy in BCR-ABL Negative MPN Patients with Underlying Portal Hypertension

Marta Davidson, Elliot Smith, Dawn Maze, Hassan Sibai, Vikas Gupta, Verna Cheung, Taylor Nye

Blood (2021) 138 (Supplement 1): 3652.

https://doi.org/10.1182/blood-2021-149696

Published: 2021

Journal Articles

Clinical Features and Long-Term Outcomes in a Molecularly-Annotated Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms

James T. England, Rouslan Kotchetkov, Hubert Tsui, Jose-Mario Capo-Chichi, Andrea Arruda, Sarah Malik, Verna Cheung, Taylor Nye, Hassan Sibai, Vikas Gupta, Dawn Maze

Blood (2021) 138 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2021-148706

Published: 2021

NARROW

Impact of Kidney Dysfunction on Overall Survival in Myeloproliferative Neoplasms: A Single-Center Retrospective Study

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Clinical Outcomes in De Novo Versus Secondary NPM1 -Mutated AML

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Which Asparaginase Formulation Retained Higher VTE Incidence Risk in Post Treatment Adult Acute Lymphoblastic Leukemia? a Meta-Analysis

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Multiparameter Flow Cytometry-Based Residual Disease Analysis Identifies Intermediate-Risk AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Germline Testing for Patients with Familial MPN: A Single-Center Experience

Enasidenib in Combination with Venetoclax in IDH2 -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial

Safety and Efficacy of JAK Inhibitor Therapy in BCR-ABL Negative MPN Patients with Underlying Portal Hypertension

Clinical Features and Long-Term Outcomes in a Molecularly-Annotated Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only